News
NCB Issues Non-Bailable Warrants Against Digital Vision Owners in ₹600-Crore Drug Diversion Case
The NCB has issued non-bailable warrants against the owners of Digital Vision, a Kala Amb–based pharmaceutical firm, in a massive ₹600-crore drug diversion racket. The investigation has uncovered large seizures of psychotropic substances and exposed an interstate supply network across seven states.
NCB Issues Non-Bailable Warrants Against Digital Vision Owners in ₹600-Crore Drug Diversion Racket
In a major development in the ₹600-crore drug diversion case, the Narcotics Control Bureau (NCB) has issued non-bailable arrest warrants against the owners of Digital Vision, a pharmaceutical company based in Kala Amb.
The firm’s owners—Purushottam Lal Goyal of Ambala and his sons Konik Goyal and Manik Goyal—are accused of illegally supplying psychotropic substances across seven states. The company came under NCB scrutiny after its partner, Anuj Kumar, was arrested on 1 November.
During the ongoing investigation, the NCB’s Special Investigation Team seized more than 611 kg of psychotropic powder, 573 kg of Tramadol bulk mixture, 1.2 million psychotropic tablets, 50,000 Tramadol ampoules and 5,000 vials of Midazolam.
With these new seizures, the agency has so far recovered over 3.4 million psychotropic tablets, 1.057 million bottles of cough syrup, 1,613 kg of raw material and 573 kg of Tramadol bulk mixture—exposing a sprawling interstate supply network valued at nearly ₹600 crore. A total of 15 people have been arrested to date.
According to investigators, Digital Vision served as a key manufacturing and supply hub for the illegal distribution of psychotropic substances. The company is alleged to have supplied large quantities of Tramadol capsules and codeine phosphate cough syrup to fake distributor firms in Jodhpur and Dehradun, which existed only on paper.
Digital Vision has faced serious allegations before. In 2020, one of its cough syrups was linked to the deaths of 12 children in Udhampur, raising major concerns about the company’s manufacturing practices.
